there is no clear evidence of increased cardiovascular risks associated with use of Olmesartan in diabetics
San Diego, CA (PRWEB) July 01, 2014
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Olmesartan.
The FDA issued a safety communication on June 24, stating that after completion of its safety review there is no clear evidence of increased cardiovascular risks associated with use of Olmesartan in diabetics. As the Agency notes, the benefits of the drug in patients with high blood pressure continue to outweigh the potential risks.
This communication on Olmesartan includes Benicar, Benicar HCT, Azor, Tribenzor, and Generics.
Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Olmesartan and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”
As the FDA advises “Patients should not stop taking olmesartan or any blood pressure medication without first discussing it with their health care professional. Recommendations for use of olmesartan remain the same, but FDA will require information about some of the studies to be included in the drug labels.”
AttorneyOne.com has further information on Olmesartan at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/06/prweb11979775.htm